Sublocade is an extended-release, subcutaneous buprenorphine injection indicated for the treatment of moderate to severe opioid use disorder in adults who are clinically stabilized on a transmucosal buprenorphine-containing medication (Health Canada, 2019). A number of jurisdictions across Canada are taking the steps necessary to implement Sublocade into existing opioid dependence treatment services, including Newfoundland and Labrador. The Centre of Excellence is currently finalizing a Sublocade bulletin in partnership with the Newfoundland and Labrador Pharmacy Board and developing a comprehensive training plan, including a webinar series, to support providers who will be prescribing and/or administering Sublocade.
Noelle Patten BSc. Pharm, MHM, RPh, CHE; Associate Registrar (QA), NL Pharmacy Board
Wayne Bishop Manager, Provincial ODT Centre of Excellence
Click here to register